In order to get a better understanding, we assessed the ability of VX-970 and the Chk1 inhibitor AZD7762[34] to sensitize a panel of 35 lung cancer cell lines to five DNA damaging drugs: cisplatin, oxaliplatin, gemcitabine, etoposide and SN38, the active metabolite of irinotecan (Figure 2, Supplementary Figures 1 and 2, Supplementary Table 1). The gene discussed is CHEK1; the disease is lung carcinoma.